Core Insights - Teladoc Health, Inc. (TDOC) shares declined by 4.2% following the release of its second-quarter 2025 results, despite reporting better-than-expected outcomes driven by international revenue growth, an expanding membership base in the Integrated Care segment, and reduced expenses [1][9] Financial Performance - The company reported an adjusted loss of $0.19 per share, which was narrower than the Zacks Consensus Estimate of a loss of $0.27 and the loss of $0.28 from the previous year [2] - Operating revenues totaled $631.9 million, down from $642.4 million year-over-year, but exceeded the consensus estimate by 1.8% [2] - Access fees revenue decreased by 6% year-over-year to $523.7 million, missing the consensus estimate by 2.2% [3] - Other revenues increased by 31% year-over-year to $108.2 million, surpassing the consensus estimate by 24.4% [3] - U.S. revenues were $519.7 million, down 4% year-over-year, but slightly beat the consensus mark by 0.2% [4] - International revenues rose by 10% year-over-year to $112.2 million, exceeding the consensus estimate by 11.3% [4] - Total expenses decreased by 53.7% year-over-year to $686.3 million, lower than the estimated $698.1 million [5] Segment Performance - The Integrated Care segment generated revenues of $391.5 million, a 4% year-over-year increase, surpassing the consensus estimate of $383 million [6] - Adjusted EBITDA for the Integrated Care segment fell by 10% year-over-year to $57.5 million, but was above the consensus mark of $53 million [6] - The BetterHelp segment's revenues declined by 9% year-over-year to $240.4 million, although it beat the consensus estimate of $237 million [7] - Adjusted EBITDA for BetterHelp fell by 53% year-over-year to $11.9 million, exceeding the consensus mark of $9.6 million [7] Membership and Visits - Total visits to Teladoc Health were 4.1 million, a 3% decline year-over-year, falling short of the consensus estimate by 0.8% [8] - U.S. Integrated Care Members reached 102.4 million as of June 30, 2025, an 11% increase year-over-year, beating the consensus mark by 0.3% [8] Cash Flow and Outlook - Cash and cash equivalents stood at $679.6 million, down from $1.3 billion at the end of 2024 [10] - Operating cash flow was $91.4 million, up from $88.7 million in the previous year [11] - Free cash inflow improved to $61.2 million from $60.9 million year-over-year [11] - For Q3, Integrated Care segment revenues are forecasted to decline by 0.5% to 2.25% growth, with an adjusted EBITDA margin expected between 14% and 15.5% [12] - Full-year revenues are projected to be between $2.501 billion and $2.548 billion, with a net loss expected between $1.00 and $1.35 per share [16]

[PART I Financial Information](index=3&type=section&id=PART%20I%20Financial%20Information) [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents Teladoc Health, Inc.'s unaudited condensed consolidated financial statements for Q2 and H1 2025, covering balance sheets, operations, and cash flows [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$2.89 billion** from **$3.52 billion** due to reduced cash, while total liabilities fell to **$1.47 billion** from **$2.03 billion** primarily from note repayment Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $679,621 | $1,298,327 | | Total current assets | $1,073,270 | $1,663,907 | | Goodwill | $283,190 | $283,190 | | Intangible assets, net | $1,383,306 | $1,431,360 | | **Total assets** | **$2,894,004** | **$3,516,524** | | **Liabilities & Equity** | | | | Total current liabilities | $401,767 | $941,535 | | Convertible senior notes, net—non-current | $993,165 | $991,418 | | **Total liabilities** | **$1,471,865** | **$2,025,445** | | **Total stockholders' equity** | **$1,422,139** | **$1,491,079** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Q2 2025 revenue decreased 2% to **$631.9 million**, while net loss significantly narrowed to **$32.7 million** from **$837.7 million** due to a prior-year goodwill impairment Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $631,900 | $642,444 | $1,261,269 | $1,288,575 | | Loss from operations | ($54,385) | ($841,148) | ($174,996) | ($928,270) | | Goodwill impairment | $0 | $790,000 | $59,138 | $790,000 | | Net loss | ($32,660) | ($837,671) | ($125,672) | ($919,560) | | Net loss per share | ($0.19) | ($4.92) | ($0.72) | ($5.44) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations increased to **$107.4 million**, while significant cash was used in investing (**$183.0 million**) and financing (**$549.2 million**) due to note repayments, resulting in a **$624.8 million** net cash decrease Cash Flow Summary for Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $107,351 | $97,603 | | Net cash used in investing activities | ($182,964) | ($63,260) | | Net cash (used in) provided by financing activities | ($549,164) | $5,556 | | **Net (decrease) increase in cash** | **($624,777)** | **$39,899** | - The significant use of cash in financing activities was due to the repayment of **$550.6 million** in convertible senior notes[16](index=16&type=chunk) - Investing activities included **$65.3 million** for a business combination (Catapult Health), **$29.6 million** for an asset acquisition (Uplift), and **$27.1 million** for other investments[16](index=16&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail revenue breakdown, recent acquisitions, a **$59.1 million** goodwill impairment, repayment of convertible notes, restructuring activities, and segment performance Revenue Breakdown for Six Months Ended June 30 (in thousands) | Revenue Source | 2025 | 2024 | | :--- | :--- | :--- | | **By Type** | | | | Access Fees | $1,049,439 | $1,116,822 | | Other | $211,830 | $171,753 | | **By Geography** | | | | U.S. Revenue | $1,044,659 | $1,088,402 | | International Revenue | $216,610 | $200,173 | | **Total Revenue** | **$1,261,269** | **$1,288,575** | - The company acquired Catapult Health for **$65.3 million** (business combination) and Uplift Health Technologies for **$29.6 million** (asset acquisition) in Q1 and Q2 2025, respectively[47](index=47&type=chunk)[49](index=49&type=chunk) - A goodwill impairment charge of **$59.1 million** was recognized in Q1 2025 for the Integrated Care reporting unit after the Catapult Health acquisition[51](index=51&type=chunk)[54](index=54&type=chunk) - The company repaid **$0.6 million** of 2025 Notes and **$550.0 million** of Livongo Notes upon maturity in May and June 2025, leaving only the **$1.0 billion** principal 2027 Notes outstanding[61](index=61&type=chunk) - Subsequent to quarter end, on July 17, 2025, the company established a new five-year, **$300.0 million** senior secured revolving credit facility[105](index=105&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the 2% revenue decrease in Q2 and H1 2025, segment performance, operational metrics, expense changes, liquidity, and cash flows, including note repayments and a new credit facility [Key Factors Affecting Our Performance](index=30&type=section&id=Key%20Factors%20Affecting%20Our%20Performance) Integrated Care saw **11%** U.S. membership growth to **102.4 million**, but chronic care enrollment and average revenue per member declined, while BetterHelp's paying users decreased **5%** in Q2 Key Operating Metrics | Metric | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | U.S. Integrated Care Members (millions) | 102.4 | 92.4 | +11% | | Chronic Care Program Enrollment (millions) | 1.117 | 1.173 | -5% | | Avg. Monthly Revenue Per U.S. Integrated Care Member | $1.27 | $1.36 | -7% | | BetterHelp Paying Users (millions, avg. for Q) | 0.388 | 0.407 | -5% | [Condensed Consolidated Results of Operations Analysis](index=33&type=section&id=Condensed%20Consolidated%20Results%20of%20Operations%20Analysis) Q2 2025 total revenue decreased **2%** to **$631.9 million**, net loss narrowed significantly to **$32.7 million**, and Adjusted EBITDA fell **23%** to **$69.3 million** - Total revenue for Q2 2025 decreased by **2%** year-over-year, primarily due to lower BetterHelp segment revenue, with acquisitions contributing approximately **2 percentage points** to growth[136](index=136&type=chunk) - Technology and development expenses decreased by **10%** in Q2 2025, mainly due to lower employee compensation costs[141](index=141&type=chunk) - A goodwill impairment of **$59.1 million** was recognized in H1 2025 related to the Catapult Health acquisition within the Integrated Care segment[144](index=144&type=chunk) Adjusted EBITDA Reconciliation Summary (in thousands) | Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 | | :--- | :--- | :--- | :--- | :--- | | Net loss | ($32,660) | ($837,671) | ($125,672) | ($919,560) | | **Adjusted EBITDA** | **$69,311** | **$89,481** | **$127,404** | **$152,621** | [Segment Information Analysis](index=39&type=section&id=Segment%20Information%20Analysis) Integrated Care revenue grew **4%** to **$391.5 million** but Adjusted EBITDA fell **10%**, while BetterHelp revenue declined **9%** to **$240.4 million** and Adjusted EBITDA dropped **53%** Integrated Care Segment Performance (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $391,510 | $377,421 | +4% | | Adjusted EBITDA | $57,450 | $64,028 | -10% | | Adjusted EBITDA Margin | 14.7% | 17.0% | -230 bps | BetterHelp Segment Performance (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $240,390 | $265,023 | -9% | | Adjusted EBITDA | $11,861 | $25,453 | -53% | | Adjusted EBITDA Margin | 4.9% | 9.6% | -470 bps | [Liquidity and Capital Resources](index=41&type=section&id=Liquidity%20and%20Capital%20Resources) The company held **$679.6 million** in cash, generated **$45.5 million** in free cash flow in H1 2025, and established a new **$300 million** revolving credit facility for enhanced flexibility - The company's primary source of liquidity is cash and cash equivalents, totaling **$679.6 million** as of June 30, 2025[166](index=166&type=chunk) Free Cash Flow Reconciliation (in thousands) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $107,351 | $97,603 | | Capital expenditures | ($3,994) | ($3,061) | | Capitalized software development costs | ($57,824) | ($60,199) | | **Free Cash Flow** | **$45,533** | **$34,343** | - On July 17, 2025, the company established a five-year, **$300.0 million** revolving credit facility to enhance financial and operational flexibility[168](index=168&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Primary market risk is interest rate volatility on cash, with a **1%** change impacting interest income by **$7.0 million** annually, alongside significant client concentration in Integrated Care - The company's principal market risk is interest rate volatility on its **$679.6 million** cash and cash equivalents; a **1%** rate change would alter annual interest income by approximately **$7.0 million**[176](index=176&type=chunk) - The Integrated Care segment faces significant client concentration risk, with its five largest customers accounting for **31%** of segment revenue in H1 2025[179](index=179&type=chunk) [Item 4. Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal controls, excluding recent acquisitions - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of June 30, 2025[182](index=182&type=chunk) - No material changes occurred in internal control over financial reporting during the quarter, with the evaluation excluding the newly acquired Catapult Health and Uplift businesses[183](index=183&type=chunk) [PART II Other Information](index=44&type=section&id=PART%20II%20Other%20Information) [Item 1. Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 15 for details on legal proceedings, including securities class actions, shareholder derivative complaints, and BetterHelp patient data lawsuits - The company is involved in various litigation matters, including securities class action complaints and shareholder derivative suits, with details provided in Note 15 of the financial statements[186](index=186&type=chunk)[88](index=88&type=chunk)[89](index=89&type=chunk) [Item 1A. Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors previously disclosed in the company's 2024 Annual Report on Form 10-K have occurred - There have been no material changes to the risk factors previously disclosed in the company's 2024 Annual Report on Form 10-K[187](index=187&type=chunk) [Item 5. Other Information](index=44&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted, terminated, or modified Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during Q2 2025 - No directors or officers adopted, terminated, or modified a Rule 10b5-1 trading plan during the three months ended June 30, 2025[189](index=189&type=chunk) [Item 6. Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Form 10-Q, including CEO/CFO certifications and XBRL data files

Group 1 - The article discusses the potential for investing in undervalued stocks that are mispriced by the market as the third quarter begins [1] - It suggests that investors should consider joining a platform that provides insights on these investment opportunities [1] Group 2 - There are no specific companies or stocks mentioned in the article, and the author has no current positions in any of the companies discussed [2] - The article emphasizes the importance of conducting personal research or consulting a financial advisor before making investment decisions [3]

Group 1 - Michael Wiggins De Oliveira is an inflection investor, focusing on buying undervalued companies at pivotal moments when their profitability is expected to improve significantly over the next year [1] - The investment strategy emphasizes technology and the Great Energy Transition, including uranium, with a concentrated portfolio of approximately 15 to 20 stocks and an average holding period of 18 months [1] - Michael has over 10 years of experience analyzing companies in tech and energy sectors, and has built a following of over 40,000 on Seeking Alpha [2] Group 2 - The Investing Group Deep Value Returns, led by Michael, offers insights through its concentrated portfolio of value stocks, timely updates on stock picks, and a weekly webinar for live advice [3] - The group provides "hand-holding" support for both new and experienced investors, fostering an active and kind community accessible via chat [3]

Core Insights - Teladoc reported revenue of $631.9 million for the quarter ended June 2025, reflecting a year-over-year decline of 1.6% and an EPS of -$0.19, an improvement from -$0.28 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $620.91 million by 1.77%, while the EPS surprised by 29.63% against the consensus estimate of -$0.27 [1] Financial Performance Metrics - U.S. Integrated Care Members reached 102.4 million, slightly above the estimated 102.12 million [4] - Average Revenue Per U.S. Integrated Care Member was $1.27, surpassing the estimated $1.25 [4] - BetterHelp Paying Users totaled 0.39 million, exceeding the average estimate of 0.38 million [4] - Chronic Care Program Enrollment matched the average estimate of 1.12 million [4] Revenue by Segment - BetterHelp generated $240.39 million in revenue, compared to the estimated $236.78 million, marking a year-over-year decline of 9.3% [4] - Integrated Care revenue was $391.51 million, exceeding the estimated $382.52 million, with a year-over-year increase of 3.7% [4] - BetterHelp's Therapy Services revenue was $235.4 million, above the average estimate of $232.77 million, reflecting a year-over-year decline of 9.1% [4] - BetterHelp's Other Wellness Services revenue was $4.99 million, below the average estimate of $5.75 million, showing a year-over-year decline of 16.2% [4] Revenue by Type - Access fees generated $523.7 million, below the average estimate of $535.21 million, representing a year-over-year decline of 6.4% [4] - Other revenue reached $108.2 million, exceeding the average estimate of $87 million, with a year-over-year increase of 30.7% [4] Adjusted EBITDA - BetterHelp's Adjusted EBITDA was $11.86 million, surpassing the average estimate of $9.58 million [4] - Integrated Care's Adjusted EBITDA was $57.45 million, exceeding the average estimate of $52.92 million [4]

Company Performance - Teladoc reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.28 per share a year ago, representing an earnings surprise of +29.63% [1] - The company posted revenues of $631.9 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.77%, although this is a decrease from year-ago revenues of $642.44 million [2] - Over the last four quarters, Teladoc has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Teladoc shares have underperformed the market, losing about 9.8% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.21 on revenues of $627.2 million, and for the current fiscal year, it is -$1.21 on revenues of $2.51 billion [7] Industry Context - The Medical Services industry, to which Teladoc belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially impact stock performance [5][8]

Financial Data and Key Metrics Changes - The second quarter consolidated revenue was $631.9 million, down 1.6% year over year, but near the high end of the guidance range [22] - Adjusted EBITDA was $69.3 million, representing a margin of 11%, also at the upper end of the guidance range [22] - Net loss per share was $0.19 compared to a net loss of $4.92 in the previous year, which included a significant goodwill impairment charge [22] - Free cash flow was $61 million in the second quarter, slightly ahead of the prior year period [23] Business Line Data and Key Metrics Changes - Integrated Care segment revenue increased by 3.7% year over year to $391.5 million, exceeding guidance [25] - U.S. Integrated Care segment membership reached 102.4 million, up 11% year over year, while virtual visit volume increased by 6% [26] - Better Health segment revenue was $240.4 million, slightly above the midpoint of guidance, but average paying users declined by 5% year over year [27][28] Market Data and Key Metrics Changes - The international integrated care business delivered mid-teens growth on a constant currency basis, contributing to overall revenue growth [25] - The U.S. cash pay users saw a high single-digit percentage decline compared to the previous year, reflecting softening consumer sentiment [29] Company Strategy and Development Direction - The company is focused on enhancing integrated care offerings, particularly in the U.S., to drive clinical outcomes and cost efficiency [12][13] - There is an emphasis on product innovation, including the launch of WellBound and enhancements to the cardiometabolic health program [6][7] - The company aims to leverage its scale in mental health and expand insurance capabilities through BetterHelp [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to a growth trajectory despite broader market dynamics impacting healthcare [21] - The company is committed to maintaining a balanced approach between financial performance and investments in strategic priorities [21] - Management highlighted the importance of virtual care in addressing healthcare challenges, including affordability and access [11][12] Other Important Information - The company has retired $551 million in convertible senior notes and has a strong cash position of $618 million [23][41] - The company is making strategic investments to scale its insurance business and enhance operational capabilities [73][74] Q&A Session Summary Question: Transition from subscription to pay-per-visit model - Management indicated that over 50% of revenues in virtual care are now from visit-based arrangements, with a significant portion in mental health being around 70% [46][47] Question: Margin differences between cash pay and insurance - Management acknowledged that insurance margins would be lower than the cash pay business, but the scale of consumer demand is expected to drive conversion rates [50][51] Question: Opportunities to drive cost in healthcare - Management emphasized the importance of access to care and the potential for virtual care to complement local delivery systems [58][60] Question: Chronic Care Solutions selling season and competition - Management noted good interest in chronic care solutions, with ongoing pressure in the health plan channel but positive activity in employer channels [64][66] Question: Revenue contribution from Better Health Insurance in 2026 - Management expects insurance revenue to scale over a 6 to 12 month period, with ongoing investments needed to support this growth [72][75] Question: Overall readiness for revenue and EBITDA growth - Management believes considerable progress has been made, but acknowledges that ongoing investments and innovations are necessary to sustain growth [78][82]

Financial Performance - Q2 2025 - Revenue for 2Q-25 was $632 million, a decrease of 2% year-over-year[5] - Net loss per share for 2Q-25 was $(0.19)[5] - Adjusted EBITDA for 2Q-25 was $69.3 million, a decrease of 23% year-over-year[5] Financial Outlook - FY25 - The company projects full year 2025 revenue to be in the range of $2,501 million to $2,548 million[6] - The company projects full year 2025 net loss per share to be in the range of $(1.35) to $(1.00)[6] - The company projects full year 2025 adjusted EBITDA to be in the range of $263 million to $294 million[6] Segment Performance - Q2 2025 - Integrated Care segment revenue for 2Q-25 was $392 million[12] - BetterHelp segment revenue for 2Q-25 was $240 million[17] - Integrated Care segment adjusted EBITDA for 2Q-25 was $57 million[14] - BetterHelp segment adjusted EBITDA for 2Q-25 was $12 million[15] Key Metrics - U S Integrated Care Members reached 102.4 million in 2Q-25[21] - BetterHelp Paying Users numbered 388 thousand in 2Q-25[24]

[Second Quarter 2025 Financial and Operational Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20and%20Operational%20Highlights) [Financial Performance Summary](index=1&type=section&id=Financial%20Performance%20Summary) Q2 2025 revenue declined 2% to $631.9 million, Adjusted EBITDA fell 23%, net loss narrowed to $32.7 million due to no prior impairment Q2 & H1 2025 Key Financial Results ($ in thousands, except per share data) | | Three Months Ended June 30, | Change | Six Months Ended June 30, | Change | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | | **2025** | **2024** | | | **Revenue** | $631,900 | $642,444 | (2)% | $1,261,269 | $1,288,575 | (2)% | | **Net loss** | $(32,660) | $(837,671) | 96% | $(125,672) | $(919,560) | 86% | | **Net loss per share** | $(0.19) | $(4.92) | 96% | $(0.72) | $(5.44) | 87% | | **Adjusted EBITDA** | $69,311 | $89,481 | (23)% | $127,404 | $152,621 | (17)% | - The significant reduction in net loss for Q2 2025 compared to Q2 2024 was largely due to a **$790.0 million** non-cash goodwill impairment charge recorded in the prior-year period[10](index=10&type=chunk) - The company retired **$550.6 million** in convertible senior notes using cash on hand and entered into a new five-year, **$300.0 million** senior secured revolving credit facility to enhance financial flexibility[7](index=7&type=chunk)[18](index=18&type=chunk) [Business Segment and Geographic Performance](index=2&type=section&id=Business%20Segment%20and%20Geographic%20Performance) Integrated Care revenue grew 4% to $391.5 million, BetterHelp declined 9% to $240.4 million, showing segment divergence Q2 2025 Performance by Segment ($ in thousands) | Segment | Revenue | YoY Change | Adjusted EBITDA | YoY Change | Adjusted EBITDA Margin | | :--- | :--- | :--- | :--- | :--- | :--- | | **Integrated Care** | $391,510 | 4% | $57,450 | (10)% | 14.7% | | **BetterHelp** | $240,390 | (9)% | $11,861 | (53)% | 4.9% | Key Operating Metrics (as of June 30, 2025) | Metric | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | U.S. Integrated Care Members (millions) | 102.4 | 92.4 | 11% | | Chronic Care Program Enrollment (millions) | 1.117 | 1.173 | (5)% | | BetterHelp Paying Users (avg. millions) | 0.388 | 0.407 | (5)% | - International revenue increased by **10%** to **$112.2 million**, while U.S. revenue decreased by **4%** to **$519.7 million** in Q2 2025[8](index=8&type=chunk)[30](index=30&type=chunk) [Cash Flow and Capital Expenditures](index=3&type=section&id=Cash%20Flow%20and%20Capital%20Expenditures) Q2 2025 operating cash flow was $91.4 million, free cash flow $61.2 million, with H1 free cash flow at $45.5 million Cash Flow Summary ($ in millions) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | **Cash Flow from Operations** | $91.4 | $88.7 | $107.4 | $97.6 | | **Capex** | $30.2 | $27.7 | $61.8 | $63.3 | | **Free Cash Flow** | $61.2 | $60.9 | $45.5 | $34.3 | [Financial Outlook](index=4&type=section&id=Financial%20Outlook) [Full Year 2025 Guidance](index=4&type=section&id=Full%20Year%202025%20Guidance) Full-year 2025 revenue projected $2,501-$2,548 million, Adjusted EBITDA $263-$294 million, anticipating segment growth divergence Full Year 2025 Outlook | Metric | Outlook Range | | :--- | :--- | | **Revenue** | $2,501 - $2,548 million | | **Adjusted EBITDA** | $263 - $294 million | | **Net loss per share** | ($1.35) - ($1.00) | | **Free Cash Flow** | $170 - $200 million | | **Integrated Care Revenue Growth** | 1.75% - 3.25% | | **BetterHelp Revenue Growth** | (9.20%) - (6.80%) | [Third Quarter 2025 Guidance](index=4&type=section&id=Third%20Quarter%202025%20Guidance) Q3 2025 revenue anticipated $614-$636 million, Adjusted EBITDA $56-$70 million, with BetterHelp revenue declining Third Quarter 2025 Outlook | Metric | Outlook Range | | :--- | :--- | | **Revenue** | $614 - $636 million | | **Adjusted EBITDA** | $56 - $70 million | | **Net loss per share** | ($0.35) - ($0.20) | | **U.S. Integrated Care Members** | 101.5 - 102.5 million | | **Integrated Care Revenue Growth** | (0.50%) - 2.25% | | **BetterHelp Revenue Growth** | (9.75%) - (5.00%) | [Consolidated Financial Statements](index=6&type=section&id=Consolidated%20Financial%20Statements) [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 revenue decreased 2%, total costs significantly lower due to no $790 million goodwill impairment, resulting in a reduced operating loss Q2 2025 Statement of Operations Highlights ($ in thousands) | Line Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Revenue** | $631,900 | $642,444 | | **Total costs and expenses** | $686,285 | $1,483,592 | | *Goodwill impairment* | *$0* | *$790,000* | | **Loss from operations** | $(54,385) | $(841,148) | | **Net loss** | $(32,660) | $(837,671) | | **Net loss per share** | $(0.19) | $(4.92) | [Condensed Consolidated Balance Sheets](index=10&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were $2.89 billion, liabilities $1.47 billion, with cash decreasing to $679.6 million Balance Sheet Highlights ($ in thousands) | Account | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $679,621 | $1,298,327 | | **Total current assets** | $1,073,270 | $1,663,907 | | **Total assets** | $2,894,004 | $3,516,524 | | **Total current liabilities** | $401,767 | $941,535 | | **Total liabilities** | $1,471,865 | $2,025,445 | | **Total stockholders' equity** | $1,422,139 | $1,491,079 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) H1 2025 generated $107.4 million from operations, used $183.0 million in investing, and $549.2 million in financing, leading to a net cash decrease Six Months Ended June 30, 2025 Cash Flow Summary ($ in thousands) | Cash Flow Activity | H1 2025 | H1 2024 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $107,351 | $97,603 | | **Net cash used in investing activities** | $(182,964) | $(63,260) | | **Net cash (used in) provided by financing activities** | $(549,164) | $5,556 | | **Net (decrease) increase in cash** | $(624,777) | $39,899 | [Non-GAAP Financial Measures and Reconciliations](index=11&type=section&id=Non-GAAP%20Financial%20Measures%20and%20Reconciliations) [Reconciliation of Net Loss to Adjusted EBITDA](index=12&type=section&id=Reconciliation%20of%20Net%20Loss%20to%20Adjusted%20EBITDA) Q2 2025 net loss of ($32.7) million is reconciled to Adjusted EBITDA of $69.3 million, after various adjustments Reconciliation of Net Loss to Adjusted EBITDA ($ in thousands) | | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net loss** | $(32,660) | $(837,671) | $(125,672) | $(919,560) | | **Total Adjustments** | $101,971 | $927,152 | $253,076 | $1,072,181 | | **Consolidated Adjusted EBITDA** | $69,311 | $89,481 | $127,404 | $152,621 | [Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow](index=12&type=section&id=Reconciliation%20of%20Net%20Cash%20Provided%20by%20Operating%20Activities%20to%20Free%20Cash%20Flow) Q2 2025 net cash from operations of $91.4 million is reconciled to free cash flow of $61.2 million, deducting Capex Reconciliation to Free Cash Flow ($ in thousands) | | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net cash provided by operating activities** | $91,432 | $88,683 | $107,351 | $97,603 | | **Capex** | $(30,233) | $(27,748) | $(61,818) | $(63,260) | | **Free Cash Flow** | $61,199 | $60,935 | $45,533 | $34,343 |

Core Insights - Teladoc Health reported a consolidated revenue of $631.9 million for the second quarter of 2025, a decrease of 2% compared to $642.4 million in the same period of 2024 [5][6] - The company achieved a net loss of $32.7 million, or $0.19 per share, significantly improved from a net loss of $837.7 million, or $4.92 per share, in the second quarter of 2024 [7][12] - Adjusted EBITDA for the second quarter of 2025 was $69.3 million, down 23% year-over-year from $89.5 million [10][15] Financial Performance - Revenue breakdown: Access fees revenue decreased by 6% to $523.7 million, while other revenue increased by 31% to $108.2 million [6][33] - U.S. revenue decreased by 4% to $519.7 million, while international revenue increased by 10% to $112.2 million [6][11] - Integrated Care segment revenue increased by 4% to $391.5 million, while BetterHelp segment revenue decreased by 9% to $240.4 million [6][35] Cost and Expenses - Total costs and expenses for the second quarter of 2025 were $686.3 million, compared to $1.5 billion in the second quarter of 2024, which included a significant goodwill impairment charge [30][9] - Stock-based compensation expense was $22.3 million for the second quarter of 2025, down from $42.1 million in the same quarter of 2024 [32][9] Cash Flow and Capital Expenditures - Cash flow from operations was $91.4 million in the second quarter of 2025, compared to $88.7 million in the second quarter of 2024 [16] - Capital expenditures were $30.2 million in the second quarter of 2025, up from $27.7 million in the same period of 2024 [16] Financial Outlook - For the full year of 2025, the company expects revenue between $2.501 billion and $2.548 billion, with adjusted EBITDA projected between $263 million and $294 million [20][21] - The third quarter of 2025 outlook includes expected revenue of $614 million to $636 million and adjusted EBITDA of $56 million to $70 million [22] Strategic Initiatives - The CEO emphasized the importance of virtual care as a performance multiplier in addressing challenges in the healthcare landscape [4] - The company is focused on enhancing patient experience, improving clinical outcomes, and driving greater value for clients [4]